reviewed. Patients were classified according to the Rome IV criteria and diagnoses assigned following clinical assessment, investigations, and follow-up, and clinical management, were recorded.

Results In total, 53/228 (27.6%) children had an FGID according to the Rome IV criteria. Sufficient information was available to make a definite FGID diagnosis using the Rome IV criteria. Sufficient information was achievable and would likely better capture the clinical burden of these common conditions through greater consistency in clinical diagnosis. In addition, use of the criteria would encourage quality improvement projects and research to better inform clinical management.

### Results

In total, 53/228 (27.6%) children had an FGID recorded.

### Background and Aim

With the exponential increase in diagnosis of non-alcoholic fatty liver disease (NAFLD) in children and young people (CYP) in the UK, the numbers of CYP attending tertiary NAFLD clinics continues to rise. Though there is no convincing evidence that pharmacological therapy can halt or reverse disease, there is strong evidence that 5–10% weight loss can improve or reverse the condition. From a liver surveillance perspective, appointments with bloods and imaging every 6–12 months are deemed sufficient, but are not adequate to support diet and lifestyle changes. The purpose of this study was to determine whether patients and their parents/carers engaged with input between appointments, and whether it improved weight loss.

### Subjects and Methods

All patients who attended NAFLD clinic requiring weight management support (January - August 2018) were offered follow up between appointments. A phone call or email was sent within six weeks of the appointment. Where phone calls were unanswered a message was left, and a letter sent if no answering service. If there was no response, no further contact attempts were made. Clinical, biochemical and anthropometric data were collected on all CYP who attended clinic; patients were reviewed 6–12 monthly. Diagnosis of NAFLD was made by paediatric hepatologist with biopsy or a combination of radiological and biochemical data on exclusion of all other known causes of liver disease. CYP were excluded if they attended another dietetic service regularly, were achieving sufficient weight loss, or weight management was not the primary reason for review. Body mass index (BMI) was calculated and converted to z-scores (WHO criteria).

### Results

During the study period 33 CYP (11%) were offered additional follow up; all agreed. Mean (SD) age was 15.0 (2.15) years at initial appointment. A phone call was requested by 17 (52%) and 16 (48%) preferred email. Contact was made with the parent/carer in 19 cases (58%) and 14 (42%) directly with the CYP. Contact was made with 15 (45%), nine (60%) by phone and six (40%) by email. Of those who received additional follow up five (33%) had a second contact and one (3%) a third contact. Mean (SD) follow up time was 37.9 (2.41) weeks. For the 24 (73%) patients with both initial and follow up data, mean (SD) BMI z-score at initial appointment was 3.19 (0.53) and follow up 3.23 (0.62). There was no difference between responders/non-responders in BMI z-score change.

### Summary and Conclusions

Although all the CYP agreed to have additional follow up, only 45% responded. The preference for contact was via phone and with parent/carer. A limitation was that only one attempt was made to reach each
EFFECTIVENESS OF HOME BOWEL PREPARATION FOR CHILDREN LIVING LONG DISTANCES FROM ENDOSCOPY CENTRE

Jamie Motion, Malcolm Sutherland, Brenda Smart, Carol Cameron, Shyla Kishore, Iain Chalmers, Su Burn. NHS Grampian

Introduction The North of Scotland Paediatric Gastroenterology, Hepatology and Nutrition Network (NoSPGHN) manages children over an area of 53,000 km². Travel distances to Royal Aberdeen Children’s Hospital (RACH) were previously felt to preclude the adoption of home bowel preparation (HBP) for elective colonoscopies but a trial period of HBP commenced in March 2020. The same drugs (senna and Picolax) were used for inpatient bowel preparation (IPBP) or HBP but the timings were changed for HBP to complete all doses on the day prior to procedure to allow travel to RACH. This audit evaluates the impact of this change of practice.

Methods All children undergoing elective colonoscopy at RACH between December 2019 and November 2020 were identified. Electronic were records reviewed to determine IPBP vs HBP; distance to RACH from patient’s home, bowel preparation score, morning or afternoon list, requirement for intravenous (IV) fluids during the procedure, day case procedure and length of stay. Bowel preparation score was derived from the Aronchick Scale and converted as follows: 0 (unacceptable), 1 (poor), 2 (fair), 3 (good) and 4 (excellent).

Results Summary The high standard of bowel preparation achieved with IPBP was maintained when delivered at home, despite some children travelling >100 miles and having travelling times of >3 hours. Delivering all doses of drugs on the day before procedure did not affect the quality of bowel preparation for afternoon lists. There is a trend to a higher proportion of children with HBP receiving IV fluids during anaesthetic which may suggest that some are dehydrated. The proportion of day case procedures has increased from 0% to 72%, which since March 2020, has saved NHS Grampian £18,000.

Conclusion Home bowel preparation delivered on day prior to procedure is well tolerated and as effective as inpatient delivered, even for children with long travelling times to hospital. Covid-19 distancing measures have reduced the number of available inpatient beds so HBP has aided bed management in addition to providing a cost saving. The risk of dehydration may be higher for HBP and guidance will be changed to increase the emphasis on oral fluid intake, including during travelling time, on day of procedure.

Efficacy of Thiopurines in Preventing Infliximab Antibody Formation When Used in Dual Therapy: Experience from a Single Tertiary Paediatric Gastroenterology Department

Muhamad Azim Muhamad Amin, Vanisha Datta, Danica Hapuarachchi, Loveday Jago, Andrew Faigemni, Ahmed Kadri. Royal Manchester Children Hospital, Manchester

Background and Aim There is evidence that shows addition of an immunomodulator (azathioprine or mercaptopurine) to Infliximab (IFX) therapy reduces antidrug antibodies, however, published evidence remains quite limited in paediatric population. We conducted a review to observe whether there is any correlation between the drug level of azathioprine metabolites, that is 6-thioguanine nucleotides (6-TGN) and development of anti-IFX antibodies (Abs) in inflammatory bowel disease (IBD) patients.

Method This is a retrospective study of patients with IBD based on a single tertiary paediatric gastroenterology department that had their levels monitored from March 2016 until March 2020. We defined maximum drug efficacy based on consensus on ESPGHAN management of IBD in paediatric and our lab references (235–450 pmol/8 × 108). In order to maintain consistencies, we included patients on 7 weekly 5 mg/kg of Infliximab infusion regimen who had their azathioprine metabolites measured within 3 months from starting. Fisher’s test and Pearson correlation were used to test the correlation between the drug level of azathioprine metabolites and development of IFX Abs.

Results 36 (58%) out of 62 patients were included in this study based on the above criteria (median age 14.25). Mean level of 6-TGN was lower in anti-IFX Abs-positive patients compared to anti-IFX Abs-negative patients (316.2 vs 322.8) with 6.607±57.51 (CI -123.5–110.3, p=0.91). There is a positive correlation between positive Anti-IFX abs with lower level of Azathioprine metabolites with coefficient at 0.47 (p=0.05).

Conclusion Our data demonstrates there is positive correlation between lower levels of azathioprine metabolites and positive anti-IFX abs level, hence suggestive of the importance of adherence to treatment to ensure longevity usage infliximab in IBD patients.